StockFin.ai Try Free →

Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 June 2026

₹6,608.5 ↓ 1.18% (1Y)

🎯 Key Takeaways

Divi's Laboratories is in a mature growth phase with strong profitability metrics but faces near-term headwinds from tax uncertainty. The company demonstrates consistent financial resilience with zero debt and robust ROCE, yet its high P/E of 72.
Revenue declined 4.1% QoQ to ₹2,604 in Q3FY26.
⚠️ The pending appeal against a ₹570.51 crore tax assessment introduces material uncertainty regarding final liability and potential penalties under Sect

Market Cap

₹1.79 L Cr

P/E Ratio

72.4

P/B Ratio

11.99

ROE

16.6%

ROCE

22.1%

Debt/Equity

0.00

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About DIVISLAB 📊 Interactive Charts

📖 The Story

Divi's Laboratories is in a mature growth phase with strong profitability metrics but faces near-term headwinds from tax uncertainty. The company demonstrates consistent financial resilience with zero debt and robust ROCE, yet its high P/E of 72.4 reflects premium valuation expectations. Recent regulatory challenges involving a ₹570.51 crore tax assessment and pending appeals introduce significant near-term risk, while dividend policy signals confidence in cash generation despite broader sectoral pressures evident in declining one-year returns.

📰 What's Happening

Management has been actively communicating financial results and strategic updates through scheduled disclosures. On February 11, 2026, Divi's Laboratories released unaudited Q3FY26 results showing consolidated total income of ₹2,692 crores (12.1% YoY growth) and announced plans to host an earnings conference call on the same date, with transcripts to be published on its website. The company also declared a ₹30 per share dividend for FY2025-26, up from ₹20, payable after the AGM on August 10, 2026, contingent on shareholder approval. Additionally, on March 21, 2026, it disclosed receipt of a Draft Assessment Order from the Income Tax Department proposing ₹570.51 crores in tax additions for FY2022-23, triggering separate penalty proceedings under Section 270A. Management confirmed intentions to appeal the order within statutory timelines, marking a critical inflection point in its regulatory trajectory.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Revenue	2,303	2,118	2,338	2,319	2,585	2,410	2,715	2,604
Operating Profit	810	701	822	825	972	848	1,033	904
OPM %	31.7%	29.4%	30.6%	32.0%	34.3%	30.3%	32.7%	34.2%
Net Profit	538	430	510	589	662	545	689	583
EPS	₹20.25	₹16.20	₹19.20	₹22.20	₹24.93	₹20.49	₹25.97	₹21.98

The company's financial trajectory over the past eight quarters reveals a pattern of revenue expansion moderated by margin compression and exceptional items. Q3FY26 revenue of ₹2,604 crores reflects a 12.1% YoY increase from ₹2,319 crores in Q3FY25, with operating profit margin holding steady at 34.2% despite a ₹74 crore exceptional charge related to labour code impacts. However, profitability declined sequentially from Q2FY26's ₹689 crores PAT to ₹583 crores in Q3FY26, driven by higher input costs and the one-time labour-related adjustment. While nine-month PAT grew 18.9% YoY to ₹1,817 crores, the quarterly trend shows increasing volatility in net earnings, suggesting sensitivity to operational and regulatory variables despite top-line resilience.

🔮 Management Outlook & What's Next

Management has not provided explicit forward-looking guidance in the reviewed filings beyond operational continuity and compliance timelines. The only forward-looking statement pertains to the appeal against the Draft Assessment Order, with management confirming it will file an appeal within the stipulated timeframe. No updated revenue, margin, or capital allocation guidance was included in the Q3FY26 results announcement or conference call scheduling notice. Management did reference ongoing monitoring of Central and State labour code clarifications, indicating potential future adjustments to employee benefits liability, but offered no quantitative forecasts. The absence of formal guidance suggests a cautious stance amid unresolved tax matters and regulatory uncertainty.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	2023-2024	2023-2024	2024-2025	2024-2025	2025-2026
Equity Capital	53	53	53	53	53
Reserves	12,624	13,518	13,664	14,916	15,360
Borrowings	2	0	5	2	89
Total Liabilities	1,606	1,899	1,869	1,963	2,738
Fixed Assets	4,648	4,733	4,652	5,437	5,672
Investments	80	82	85	65	67
Total Assets	14,283	15,470	15,586	16,932	18,151

The balance sheet reflects a strong capital structure with negligible debt (₹89 crores borrowings) and substantial reserves of ₹15,360 crores, supporting financial flexibility. Equity remains stable at ₹53 crores, underscoring that growth has been primarily funded through retained earnings rather than equity dilution. Total assets have grown steadily from ₹15,586 crores in 2024-25 to ₹18,151 crores in 2025-26, driven by reinvestment of operating cash flows. This conservative leverage profile enables strategic flexibility, whether for capex, debt reduction, or shareholder returns, though the lack of visible debt reduction suggests capital is being deployed selectively rather than aggressively deleveraging.

💰 Cash Flow Statement (₹ Cr)

Item	2020-2021	2020-2021
Operating	+1,158	+1,947
Investing	+580	+75
Financing	-34	-35
Net Cash Flow	—	—

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA TORNTPHARM CIPLA DRREDDY LUPIN

⚠️ Risk Factors

1. The pending appeal against a ₹570.51 crore tax assessment introduces material uncertainty regarding final liability and potential penalties under Section 270A, which could impact earnings and reputation. 2. Ongoing labour code implementation may lead to additional liabilities or adjustments to employee benefit provisions, affecting future cash flows. 3. Despite strong revenue growth, quarterly PAT declined 1.2% YoY in Q3FY26, signaling margin pressure from rising input costs that management has not yet quantified. 4. The high P/E multiple of 72.4 implies significant market expectations, making the stock vulnerable to any negative revision in earnings outlook amid unresolved regulatory or operational headwinds.

📋 Recent Filings

🧠 Analyst's Read

Investors should monitor the outcome of the tax appeal and clarity on labour code liabilities as near-term catalysts, alongside quarterly margin trends and international API demand patterns. The company's financial resilience remains intact, but earnings visibility is constrained by regulatory uncertainty and sector-specific cost pressures, making execution risk a key determinant of future performance.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on DIVISLAB

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.